Acorah Software Products - Accounts Production 16.8.310 false true 31 October 2024 1 November 2023 false 1 November 2024 31 October 2025 31 October 2025 11644202 Dr M Akil Dr H M Akil iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 11644202 2024-10-31 11644202 2025-10-31 11644202 2024-11-01 2025-10-31 11644202 frs-core:CurrentFinancialInstruments 2025-10-31 11644202 frs-core:ComputerEquipment 2025-10-31 11644202 frs-core:ComputerEquipment 2024-11-01 2025-10-31 11644202 frs-core:ComputerEquipment 2024-10-31 11644202 frs-core:RevaluationReserve 2024-11-01 2025-10-31 11644202 frs-core:RevaluationReserve 2024-10-31 11644202 frs-core:RevaluationReserve 2025-10-31 11644202 frs-core:ShareCapital 2025-10-31 11644202 frs-core:RetainedEarningsAccumulatedLosses 2024-11-01 2025-10-31 11644202 frs-core:RetainedEarningsAccumulatedLosses frs-core:PreviouslyStatedAmount 2024-10-31 11644202 frs-core:RetainedEarningsAccumulatedLosses 2025-10-31 11644202 frs-bus:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 11644202 frs-bus:FilletedAccounts 2024-11-01 2025-10-31 11644202 frs-bus:SmallEntities 2024-11-01 2025-10-31 11644202 frs-bus:AuditExempt-NoAccountantsReport 2024-11-01 2025-10-31 11644202 frs-bus:SmallCompaniesRegimeForAccounts 2024-11-01 2025-10-31 11644202 frs-core:DeferredTaxation 2024-11-01 2025-10-31 11644202 frs-core:DeferredTaxation 2024-10-31 11644202 frs-core:DeferredTaxation 2025-10-31 11644202 frs-core:UnlistedNon-exchangeTraded 2025-10-31 11644202 frs-core:UnlistedNon-exchangeTraded 2024-10-31 11644202 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2024-10-31 11644202 frs-core:RevaluationsIncreaseDecreaseInInvestments frs-core:UnlistedNon-exchangeTraded 2025-10-31 11644202 frs-core:CostValuation frs-core:UnlistedNon-exchangeTraded 2025-10-31 11644202 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2024-10-31 11644202 frs-core:ProvisionsForImpairmentInvestments frs-core:UnlistedNon-exchangeTraded 2025-10-31 11644202 frs-bus:Director1 2024-11-01 2025-10-31 11644202 frs-bus:Director2 2024-11-01 2025-10-31 11644202 frs-countries:EnglandWales 2024-11-01 2025-10-31 11644202 2023-10-31 11644202 2024-10-31 11644202 2023-11-01 2024-10-31 11644202 frs-core:CurrentFinancialInstruments 2024-10-31 11644202 frs-core:RevaluationReserve 2024-10-31 11644202 frs-core:ShareCapital 2024-10-31 11644202 frs-core:RetainedEarningsAccumulatedLosses 2024-10-31
Registered number: 11644202
Peakside Medical Ltd
Unaudited Financial Statements
For The Year Ended 31 October 2025
Peakside Medical Ltd
Contents
Contents

| Page
--- | ---
Balance Sheet | 1—2
Notes to the Financial Statements | 3—5

Page 1
Peakside Medical Ltd
Balance Sheet
As At 31 October 2025
Balance Sheet
Registered number: 11644202

| 2025 | 2024
--- | --- | ---
| Notes | £ | £ | £ | £
FIXED ASSETS
Tangible Assets | 4 |  | 125 |  | 625
Investments | 5 |  | 59,803 |  | 53,329
|  |  | 59,928 |  | 53,954
CURRENT ASSETS
Debtors | 6 | 13,253 |  | 18,634 |
Cash at bank and in hand |  | 573,050 |  | 452,412 |
|  | 586,303 |  | 471,046 |
Creditors: Amounts Falling Due Within One Year | 7 | (43,733 ) |  | (44,276 ) |
NET CURRENT ASSETS (LIABILITIES) |  |  | 542,570 |  | 426,770
TOTAL ASSETS LESS CURRENT LIABILITIES |  |  | 602,498 |  | 480,724
PROVISIONS FOR LIABILITIES
Deferred Taxation | 8 |  | (24 ) |  | (119 )
NET ASSETS |  |  | 602,474 |  | 480,605
CAPITAL AND RESERVES
Called up share capital | 10 |  | 60 |  | 40
Revaluation reserve | 11 |  | 7,238 |  | 1,752
Profit and Loss Account |  |  | 595,176 |  | 478,813
SHAREHOLDERS' FUNDS |  |  | 602,474 |  | 480,605

Page 1
Page 2
Peakside Medical Ltd
Balance Sheet (continued)
As At 31 October 2025
For the year ending 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
On behalf of the board

Dr M Akil Director
04/02/2026

The notes on pages 3 to 5 form part of these financial statements.
Page 2
Page 3
Peakside Medical Ltd
Notes to the Financial Statements
For The Year Ended 31 October 2025
Notes to the Financial Statements
1. General Information
Peakside Medical Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 11644202 . The registered office is 174 Dore Road, Dore, Sheffield, S17 3HA.
2. Accounting Policies
2.1. Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2. Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
2.3. Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Computer Equipment | 25% straight line

2.4. Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other year and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences.
3. Average Number of Employees
Average number of employees, including directors, during the year was: 2 (2024: 1)
2 1
4. Tangible Assets

| Computer Equipment
--- | ---
| £
Cost
As at 1 November 2024 | 4,360
Disposals | (2,360 )
As at 31 October 2025 | 2,000
Depreciation
As at 1 November 2024 | 3,735
Provided during the period | 500
Disposals | (2,360 )
As at 31 October 2025 | 1,875
Net Book Value
As at 31 October 2025 | 125
As at 1 November 2024 | 625

Page 3
Page 4
Peakside Medical Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 October 2025
5. Investments

| Unlisted
--- | ---
| £
Cost or Valuation
As at 1 November 2024 | 53,329
Revaluations | 6,474
As at 31 October 2025 | 59,803
Provision
As at 1 November 2024 | -
As at 31 October 2025 | -
Net Book Value
As at 31 October 2025 | 59,803
As at 1 November 2024 | 53,329

6. Debtors

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Due within one year
Trade debtors | 13,253 |  | 18,634

7. Creditors: Amounts Falling Due Within One Year

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Corporation tax | 37,563 |  | 35,863
Accruals and deferred income | 1,437 |  | 1,626
Directors' loan accounts | 4,733 |  | 6,787
| 43,733 |  | 44,276

8. Deferred Taxation
The provision for deferred tax is made up as follows:

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Other timing differences | 24 |  | 119

9. Provisions for Liabilities

| Deferred Tax | Total
--- | --- | ---
| £ | £
As at 1 November 2024 | 119 | 119
Deferred taxation | (95 ) | (95 )
Balance at 31 October 2025 | 24 | 24

Provision is made for the potential charge to tax that would arise should the company dispose of its fixed assets at the stated net book value to the extent that this is in excess of the tax written down value.
Page 4
Page 5
Peakside Medical Ltd
Notes to the Financial Statements (continued)
For The Year Ended 31 October 2025
10. Share Capital

| 2025 |  | 2024
--- | --- | --- | ---
| £ |  | £
Allotted, Called up and fully paid | 60 |  | 40

11. Reserves

| Revaluation reserve | Profit and Loss Account
--- | --- | ---
| £ | £
As at 1 November 2024 | 1,752 | 478,813
Profit for the year and total comprehensive income | - | 124,049
Dividends paid | - | (2,200)
Transfer from revaluation reserve | - | (5,486)
Transfer to/from Profit & Loss Account | 5,486 | -
As at 31 October 2025 | 7,238 | 595,176

Page 5